※一部利用できない機能があります
Study protocol: high-dose mizoribine with prednisolone therapy in short-term relapsing steroid-sensitive nephrotic syndrome to prevent frequent relapse (JSKDC05 trial)
- 資料種別:
- 論文(リポジトリ)
- 責任表示:
- Hama, Taketsugu ; Nakanishi, Koichi ; Ishikura, Kenji ; Ito, Shuichi ; Nakamura, Hidefumi ; Sako, Mayumi ; Saito-Oba, Mari ; Nozu, Kandai ; Shima, Yuko ; Iijima, Kazumoto ; Yoshikawa, Norishige
- 言語:
- 英語
- 出版情報:
- Springer Nature, 2018-09-10
- 著者名:
Hama, Taketsugu Nakanishi, Koichi Ishikura, Kenji Ito, Shuichi Nakamura, Hidefumi Sako, Mayumi Saito-Oba, Mari Nozu, Kandai Shima, Yuko Iijima, Kazumoto Yoshikawa, Norishige - 掲載情報:
- BMC Nephrology
- ISSN:
- 1471-2369
- 巻:
- 19
- バージョン:
- VoR
- 概要:
- Background: Eighty percent of children with steroid-sensitive nephrotic syndrome (SSNS) relapse within 2 years and 40-50% patients show frequently-relapsing nephrotic syndrome (FRNS). Patients showing a relapse within 6 months after initial
…
remission are at high risk of FRNS. Since frequent prednisolone treatment for FRNS induces severe prednisolone side effects, development of a treatment to prevent patients from shifting to FRNS is desirable. Mizoribine is an immunosuppressive drug with fewer side effects than prednisolone. Recent studies reported the efficacy of high-dose mizoribine in children with FRNS. Methods/design: We conduct a multicenter, open, randomized controlled trial to investigate the efficacy and safety of standard prednisolone plus high-dose mizoribine therapy in children with SSNS showing a relapse within 6 months after an initial remission. Patients are allocated to either standard prednisolone alone treatment group, or standard prednisolone plus high-dose mizoribine group. For the former group, mizoribine is administered at a dose of 10 mg/kg/day once daily and continued for 2 years. The primary endpoint is the duration to frequent relapse. Discussion: The results provide important data on use of high-dose mizoribine to prevent SSNS patients from shifting to FRNS. Since blood concentrations of mizoribine have not been investigated in detail until now, there is a possibility that mizoribine is underestimated in favor of other immunosuppressive drugs. In future, high-dose mizoribine therapy may lead to prevention of relapse in children at high risk of FRNS, and to decreased total dose of prednisolone.
論文 続きを見る - URL:
- http://hdl.handle.net/20.500.12000/45852